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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder of our times.
The spectrum of this disease goes from steatosis to non-alcoholic steatohepatitis (NASH),
cirrhosis and hepatocellular carcinoma. NAFLD can appear in the context of many condi‐
tions. Probably, NAFLD could be a component of metabolic syndrome, with its complete
phenotypic expression: insulin resistance, obesity, type 2 diabetes, hypertension, hypercho‐
lesterolemia, and hypertriglyceridemia.
The pathogenesis involves insulin resistance, hepatic fat deposition, increased oxidant
stress, apoptosis, inflammation and fibrosis. At present day, a new hormone has been dis‐
covered. Muscle cells products this new hormone, called irisin. Irisin can induce changes in
adipose tissue.
Diagnosis of NAFLD cannot be performed with a single test and it should be one of exclu‐
sion, as well.
Nowadays, there is not a single therapeutic intervention. The focus of management should
be treatment of the risk factors for NASH (insulin resistance, obesity…). Principal methods
used for weight management are dietary modifications and life style changes. Then, phar‐
macotherapy may include insulin sensitizers, cholesterol-lowering agents, anti-obesity and
anti-oxidant agents. Morbid obese patients may benefit from surgical weight loss, reducing
the progression of NASH.
2. Definition
NAFLD definition [1] requires that there is evidence of hepatic steatosis, either by imaging
or by histology and there are no causes for secondary hepatic fat accumulation (Table 1).
© 2012 Cabezas et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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NAFLD is usually associated with metabolic risk factors such as metabolic syndrome, obesi‐
ty, diabetes mellitus, and dyslipidaemia.
COMMON CAUSES OF SECONDARY HEPATIC STEATOSIS
Macrovesicularsteatosis
Excessive alcohol consumption.
Hepatitis C (genotype 3)
Wilson’s disease.
Lipodistrophy
Starvation
Parenteral nutrition.
Abetalipoproteinemia.
Medication (amiodarone, methotrexate, tamoxifen, corticosteroids)
Microvesicularstatosis
Reye’s syndrome.
Medications (valproate, anti-retroviral medicines)
Acutte fatty liver of pregnancy
HELLP syndrome
Inborn errors of metabolism (LCAT deficiency, cholesterol ester storage disease, Wolman disease)
Table 1. Causes of secondary fat accumulation.
NAFLD includes a constellation of histological findings that goes from steatosis, to necroin‐
flammation, called NASH and progression to advanced fibrosis and cirrhosis.
3. Epidemiology
NAFLD is becoming the leading cause of liver disease. One of the causes is the increasing of
obesity[2].
The incidence of NAFLD has been evaluated in a few number of studies, it ranges from
31-86 cases/1000 person-year in Japan to 29 cases per 100000 person-year in England [3, 4].
The prevalence of NAFLD is increasing. Recent studies presented in the Digestive Diseases
Week 2012 summarizes this increased prevalence over the last 20 years [5, 6]. Investigators
report an increasing in obesity. This increase is followed by a rising in steatosis and NASH,
the presence of steatosis among obese people has increased from 23% in the 80s, 43% in the
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90s and finally to 60% nowadays [4]. Even in non-obese patients, the prevalence of steatosis
increased from 12%, to 27% and 36%, respectively [5].
In children/adolescents, over the last 20 years, obesity has increased from 11% to 21%, sus‐
pected NAFLD from 4% to 10, and the prevalence of altered aminotransferases among obese
adolescents has increased from 17% to 37% [6].
4. NAFLD and liver biopsy
Liver biopsy remains the gold standard for characterizing liver histology in patients with
NAFLD. However, it is expensive and carries some morbidity and very rare mortality risk.
Thus, it should be performed in those who would benefit the most from diagnostic, thera‐
peutic guidance, and prognostic perspectives.
The last guideline for NAFLD management recommends liver biopsy [1]: in patients who
are at risk to have steatohepatitis and advance fibrosis; theses patients could be identified by
the presence of metabolic syndrome and NAFLD fibrosis score; and a liver biopsy should be
considered in patients in whom other etiologies are suspected and cannot be excluded with‐
out a liver biopsy.
Liver biopsy allows confirming the diagnosis, evaluation and semiquantitation of necroin‐
flammatory lesions and fibrosis.
On the other hand, liver biopsy suffers from challenges. An adequate biopsy represents only
1/50000-1/65000 of the organ. Sampled area should be carefully chosen and sample length
must be enough, a least 15mm. This size can reduce sample error. Finally, experienced path‐
ologist is important to haver a greater yield of findings.
5. Histology of NAFLD
NAFLD represents a histopathologic spectrum ranging from steatosis alone, to necroinflam‐
mation, summarized as NASH; and progression to advanced fibrosis and cirrhosis.
The histologic characterization of NAFLD and NASH may include description of steatosis
and cell injury in addition to inflammation and fibrosis. Kleiner and Brunt [7] propose cate‐
gorizing the histologic changes when studying NAFLD as follows in table 2.
The main histological characteristic of NAFLD is the accumulation of fat in the form of tri‐
glyicerides within hepatocytes, lesion termed steatosis (Figure 1 and 2); this term is defined
by the guideline [1] as NAFL – non-alcoholic fatty liver, where the risk of progression to cir‐
rhosis and liver failure is minimal. The presence of >5% steatoic hepatocytes in a liver biopsy
is accepted as the minimum criterion for thehistological diagnosis of NAFLD [8].
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CATEGORY DEFINITION
No significant evidence of fatty liver disease. Insufficientsteatosis for diagnosis of steatosis, without
other changes (ballooning, fibrosis) that would suggest
steatohepatitis.
Steatosis:
Steatosis with inflammation.
Steatosis with nonspecific fibrosis
Steatosis without specific changes to suggest a form of
steatohepatitis. This category may include spotty lobular
inflammation and/or mild degrees of fibrosis of uncertain
significance.
Steatohepatitis:
- zone 3 borderline steatohepatitis
Form of steatoshepatitis most common in adults; defined
as a zone 3 centered injury pattern that includes steatosis,
inflammation, ballooning injury, (often with Mallory-Denk
bodies) with or without fibrosis. Borderline
steatohepatitsis has some, but not all ofthe features that
would allow a diagnosis of steatohepatitis.
Zone 1, borderline pattern Form of steatohepatitis that occurs mainly in young
children, characterized by zone 1-centered (portal
inflammation, portal-based fibrosis, zone 1 steatosis,
ballooning injury in zone 1 if present).
Cryptogenetic fibrosis/ cirrhosis Presence of fibrosis (usually advanced) or cirrhosis, with
little ton o steatosis and no changes (ballooning, Mallory-
Denk bodies) that would suggest borderline or definite
steatohepatitis. Other explanations for fibrosis (besides
steatohepatitis) should be considered.
Table 2. Histologic Categorization of NAFLD [7].
Figure 1. Steatosis. Hematoxylin-eosin stain.
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Figure 2. Steatosis. Hematoxylin-eosin stain.
Steatosis in NAFLD is usually macrovesicular, which refers to hepatocytes with single large
intracytoplasmatic fat droplet or smaller well defined droplets displacing the nucleus to the
cell periphery. This macrovesicularsteatosis is usually present in a zone 3 or panacinar dis‐
tribution; it differs from zone 1 steatosis that is a common distribution in chronic hepatitis C.
Azonal steatosis is most often seen in biopsies with advanced fibrosis [9].
The extent of steatosis can be evaluated and classified semi-quantitative. The most reprodu‐
cible method follows the acinararchiqueture dividing the liver parenchyma in thirds and as‐
sessing percentage involvement bay steatoic hepatocytes [8] – table 3.
STEATOSIS SEMI-QUANTIFICATION
Mild 0 – 33%
Moderate 33 – 66%
Severe > 66%.
Table 3. Steatosis semi-quantification according to acinar architecture [8].
NASH, under this concept is the histology pattern of NAFLD, which is at risk of developing
advance fibrosis. The minimal criteria for the histopathological diagnosis of adult NASH in‐
clude steatosis, hepatocyte injury, usually in form of ballooning, and lobular inflammation,
typically localized in acinar zone 3 [10, 11].
The key feature for the diagnosis of NASH is the ballooning injury (Figures 3 and 4), and it
is considered a marker of apoptosis [12]. This type of cell injury is characterized by a cell
that becomes enlarged and the cytoplasm becomes irregularly clumped with optically clear,
nonvesiculated areas. Ballooned cells are seen most frequently in zone 3 near the hepatic
veins, and lose this localization, becoming portal inflammation more prominent when the
disease progresses and in severe cases. Immunostaining of hepatocyte keratins 8 and 18
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might help to identify ballooned hepatocytes [13]. Ballooned degeneration is difficult to di‐
agnose even by trained pathologist, for that reason it can show significant inter-observer
variation [14].
Figure 3. Hepatocyte ballooned. Hematoxylin-eosin stain.
Ballooning degeneration is associated with an increased liver-related mortality [15].
Figure 4. Ballooning hepatocyte. Hematoxylin-eosin stain.
Mallory-Denk Bodies (MDB), also known as Mallory bodies, are eosinophilic, ropey cyto‐
plasmatic inclusion bodies in the hepatocyte of patients with chronic liver disease. This type
of lesion contains abnormal cytokeratin 8 and 18 filaments that have been ubiquinated.
Mallory bodies have an importance in disease progression and it is suggested a possible
prognostic role in steatohepatitis [16]. In a recent study, the presence of MBD was signifi‐
cantly associated with liver-related mortality [15].
Both ballooning degeneration and MDB can trigger the development of apoptosis. Apoptot‐
ic (acidophil) bodies are common in NASH. They can be identified as rounded, eosinophilic
cytoplasmic fragments, which appear to be free within the sinusoids or surrounded by
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Kupffer or other inflammatory cells. Apoptosis has been validated as an accurate marker for
diagnosis of NASH based on immunochemistry in liver tissue [17].
Inflammatory infiltrates (Figure 5) can be seen in the hepatic acini/lobules or the portal tract.
Lobular inflammation is usually mild, consists of a mixed inflammatory cell infiltrate, com‐
posed of lymphocytes, some eosinophils, and a few neutrophils. Polymorphs can be ob‐
served around ballooned hepatocytes that are called “satellitosis” (Figure 6). Kuppfer cells
aggregates as lobular microgranulomas and lipogranulomas may appear [10]
Figure 5. Mononuclear inflammatory infiltration. Hematoxylin-eosin stain.
Figure 6. Polymorph around ballooned hepatocytes, “satelitosis”.
Hematoxylin-eosin stain.Portal chronic mononuclear cell inflammation in adult NASH is
common and mild. When portal inflammation is greater than lobular other aetiologies
should be ruled out, such as chronic hepatitis C [18]. On the other side, a greater portal in‐
flammation than lobular inflammation can be seen in successfully treated patients [19]. In a
large database of liver biopsies from the NASH Clinical Research Network, including adults
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and children, portal chronic inflammation was associated with clinical and histologic fea‐
tures of severity and advance disease [20].
Vascular alterations in NAFLD. Recent paper has focused the study of NASH in microves‐
sels of the liver [21]. This work has found an intraacinar branch of the hepatic artery in the
perivenular region in active steatohepatitis. This finding is important because it can lead to
confusion for a portal tract resulting in an equivocal diagnosis. Likewise, the presence of this
vessel correlates with higher stage of fibrosis.
Fibrosis in adult NASH usually starts in acinar zone 3 and has characteristic “chicken wire”
pattern due to deposition of collagen an other extracellular matrix fibres along the sinusoids
of zone 3 and around the hepatocytes (Figure 7 and 8). Portal fibrosis has been reported in
cases of morbid obesity-related NASH and in pediatric NASH. Fibrosis predicts clinical out‐
comes in NASH [22]. there was noter from this study that the progression of the fibrosis is
accompanied of steatosis reduction. Approximately 37% to 41% of patients with NAFLD
have fibrosis progression over 3 to 10 years [22, 23]. The higher rates of fibrosis progression
were related to: body mass index, diabetes and low initial fibrosis [22]. When periportal fib‐
rosis was not present, there was a 100% of negative predictive value in predicting liver-relat‐
ed outcomes [23]. Steatosis, inflammation, ballooning and Mallory hyaline were not
associated with liver-related mortality after adjusting for the presence of fibrosis [15]. The
inclusion of fibrosis explains why the recent classifications for NASH used by Younossi [15]
and Matteoni [16], independently correlated with liver-related mortality. This observation
shows the importance of fibrosis in NAFLD, patients with NASH and fibrosis portends a
higher risk of death [24].
Figure 7. Fibrosis pattern: around hepatocytes. Masson trichrome stain.
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Figure 8. Zone 3 fibrosis perivenular/pericellular. Masson trichrome stain.
Other histological lesions that may be seen in NASH include megamitochondria, glycogen‐
ated nuclei and iron deposition.
Megamitochondria (giant mitochondria) are round or needle-shaped, eosinophilic, intracy‐
toplasmatic inclusions more commonly observed in hepatocytes with microvesicularsteato‐
sis. This abnormal mitochondria is a result of injury from lipid peroxidation or represent an
adaptive change [25]. Glycogenated nuclei are vacuolated nuclei usually observed in peri‐
portal hepatocytes. Their presence is more frequent in non-alcoholic etiology and it is rare in
alcoholic injury [26].
Finally, hepatic siderosis might be seen in NAFLD. One study of 293 liver biopsies (34,5% of
patients with NAFLD) investigates the relationship between iron deposition and NAFLD
[27]. Stainable hepatic iron described three histological patterns: hepatocellular pattern, re‐
ticuloendothelial system cell – RES - (mainly Kupffer cell) pattern and mixed. RES pattern
was associated with advanced fibrosis and higher histological features of portal inflamma‐
tion, ballooning and definite NASH [27].
6. Histologic scoring systems
NAFLD histologic criteria requires an accumulation of more than 5% of fat deposition,
mainly in form of triglycerides. NAFLD was first described by Ludwig and colleagues [28],
and since then several systems for grading and staging NAFLD have been proposed.
In 1999, Matteoni and colleagues characterized histologic subtypes that correlate with clini‐
cal outcomes [16] – table 4. In 2005, NASH Clinical Research Network developed NAFLD
activity score (NAS) [8]. This score comprises four features evaluated semi-quantitatively:
steatosis, lobular inflammation, hepatocellular ballooning and fibrosis. Fibrosis was classi‐
fied separately – table 5. When NAS is >5 sensitivity and specificity for definite NASH were
0,75 and 0,83, respectively. Finally, a recent classification for NAFLD has been proposed by
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Younossi and colleagues [15]. This classification includes the evaluation of these histologic
features: steatosis with centrilobular ballooning, and/or Mallory-Denk bodies of fibrosis –
see table 6.
CLASSIFICATION OF NONALCOHOLIC LIVER FATTY LIVER DISESASE (NAFLD) BY SUBTYPE
NAFLD subtype Pathology Clinicopathologic correlation
Type 1 Simple steatosis alone No NASH
Type 2 Statosis + lobular inflammation only No NASH
Type 3 Steatosis + hepatocellular ballooning NASH without fibrosis
Type 4 Steatosis, ballooning, Mallory bodies or fibrosis NASH with fibrosis
Table 4. Classification of NAFLD by subtype [16].
CLASSIFICATION OF NONALCOHLIC FATTY LIVER DISEASE BY NAFLD CLINICAL RESEASCH NETWORK
Histologic finding Score
Steatosis 0-3
Lobular inflammation 0-3
Hepatocellular ballooning 0-2
NASH requires a score of ≥ 4 with at least 1 point o ballooning injury.
Fibrosis type Score
None 0
Perisinusoidal zone 3
Mild 1A
Moderate 1B
Portal/periportal 1C
Persinusoidal and portal/periportal 2
Bridging 3
Cirrhosis 4
Table 5. Classification of NAFLD by NAFLD CRN [8].
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CLASSIFICATION OF NAFLD BY SUBTYPE
Pathology Clinicopathologic
correlation
Simple steatosis alone No NASH
Steatosis + lobular inflammation only No NASH
Steatosis with centrilobular ballooning and/or Mallory-Denk bodies NASH
Any steatosis with centrilobularpericellular/perisinusoidal or briding fibrosis NASH
Table 6. Classification of NAFLD proposed by Younossi and colleagues [15].
The most important difference between NAS and subtype classifications is that the latters
include fibrosis and this provides a better prediction of liver-related mortality in patients
with NAFLD [15].
7. NAFLD in special populations
Patients with insulin resistance. Insulin resistance can be estimated using the homeostasis
model for assessing of insulin resistance (HOMA-IR), calculated as the product of fasting in‐
sulin level (mUI/ml) and plasma glucose level (mmol/ml), divides by 22,5 [29]. Portal fibro‐
sis has been linked to the ductular reaction (ductularproliferation at the portal tract interface
arising from progenitor cells in the periportal area and accompanied by neutrophils and
stromal changes). These findings correlate the insulin resistance with advanced stages of fib‐
rosis and provide a pathway for fibrosis progression [30].
In some cases in a study with a few number of patients treated with an insulin sensitizer,
histologic evaluation of post-treatment liver biopsy showed that increased portal inflamma‐
tion is a feature related to resolution of NASH, and it is associated to a change in the quality
of zone 3 perisinusoidal fibrosis from dense to delicate [19].
NAFLD  in  bariatric  surgery  patients.  Patients  undergoing  bariatric  surgery  for  weight
loss are at a risk of NAFLD. They often have comorbidities such as: severe obesity, diabe‐
tes, hypertension, sleep apnea or coronary artery disease. And high percentage will have
metabolic  syndrome [31]  (see table 7).  The prevalence of  steatosis  and steatohepatitis  in
these patients undergoing liver biopsy when surgery is  performed, is  91% and 37%, re‐
spectively [32]. At least a third of morbidity obese patients have portal inflammation, and
this is related to the presence of fibrosis [20, 33]. In early stage, localization of fibrosis dif‐
fers from those nonbariatric populations, in bariatric is portal and in nonbariatric is perisi‐
nusoidal [19].
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The Adult Treatment Panel III clinical definition of the metabolic syndrome:
- Requires the presence of three or more of the following features:
Waist circumference greater than 102 cm in men or greater than 88 cm in women.
Triglyceride level 150mg/dl or greater.
High-density lipoprotein (HDL) cholesterol level less than 40 mg/dl in men and less than 50 mg/dl in women.
Systolic blood pressure 130 mmHg or greater or diastolic pressure 85 mmHg or greater.
Fasting plasma glucose level 110 mg/dl or greater.
Table 7. Definition of the metabolic syndrome [31].
NAFLD after bariatric surgery. Improvements of major histological features of disease ac‐
tivity, grade of steatohepatitis and rarely fibrosis following therapy (dietary, medicines or
surgery) have been reported [34]. After surgical intervention liver histology improve in
these features: lobular steatosis, necroinflammatory changes and fibrosis, against no im‐
prove in portal abnormalities [35]. Recent meta-analysis [36] shows that patients after bariat‐
ric surgery have improvement or resolution in steatosis (91,6%), in steatohepatitis (81,3%), in
fibrosis (65,5%) and for complete resolution of NASH was 69,5%.
In the near future, we will have to get used to new types of treatment, for example, “meta‐
bolic surgery”, which might be performed to non-morbid obese patients with diabetes, and
to the new changes in hepatic parenchyma following endoscopic procedures performed to
treat obesity.
NAFLD in children. Pediatric NAFLD can have a different histologic presentation than
adult NAFLD. In the first large biopsy series of pediatric NAFLD [37], two different histo‐
logic patterns were described with differences in race and gender. Type 1 NASH: similar to
adults, more common in Caucasian children. Histologic characteristics are: steatosis, bal‐
looning degeneration and perisinusoidal fibrosis. On the other hand, Type 2 NASH was
more common in Asian, Native American and Hispanics. Typical features in the liver biopsy
are: steatosis with lymphocytic portal inflammation and portal fibrosis. Children with type 2
were younger and had a greater severity of obesity, and advanced fibrosis. This kind of pat‐
tern was described in adult morbid obese patients undergoing bariatric surgery, these pa‐
tients mean age were slightly lower [33]. Overlap cases with characteristic of both
histological types may also be observed in pediatric NASH. A multicentre retrospective co‐
hort study reviewed 130 liver biopsies of children according to these criteria of pediatric
NAFLD [38]. The majority of the biopsies presented an overlapping pattern (82%). Ad‐
vanced fibrosis was associated with the presence of lobular and portal inflammation.
Portal fibrosis is common in pediatric NAFLD and may evolve to periportal fibrosis and
bridging  fibrosis  in  some patients,  whereas  progression  to  cirrhosis  is  observed in  rare
cases [39].
It is not clear, that Type 2 NASH, described as pediatric NASH, is an entity by itself or it is
another stage of the spectrum of NASH which could be a predictor of those who have a se‐
vere disease [40].
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8. Imaging tecnology in NAFLD
Ultrasonography (US), computed tomography (CT), and magnetic resonance (MR) can identi‐
fy liver steatosis but not steatohepatitis, nevertheless they provide anatomical and morpholog‐
ical information. The sensitivity of these imaging methods is optimal for steatosis over 33%.
When advance liver disease, radiology techniques can provide indirect signs of cirrhosis, such
as portal hypertension, or may be useful for the screening and diagnosis of hepatocellular carci‐
noma (HCC)[41]. Imaging technique may help to differentiate diffuse from focal form of steato‐
sis. Hepatic fatty infiltration can present as focal steatosis (a focal area of steatosis in an
otherwise normal liver) or as focal fatty sparing (fatty change with sparing of certain areas) [42].
Abdominal US is the most commonly used imaging technique to clinically evaluate the pres‐
ence of liver steatosis. Advantages include low cost, lack of radiation exposure and wide availa‐
bility. The brightness of the liver echo is compared with the kidney, the attenuation of the
sound beam by the fat results in relatively hypoechoic kidney. For detailed description of sono‐
graphic features for staging fatty liver see table 8. This US feature is not characteristic of NAFLD
because it can be present in other diffuse parenchymal liver disease. The US can be accurate de‐
tecting hepatic steatosis when there is a moderate to severe infiltration [43]. Overall sensitivity
and specificity are 60-94% and 66-95%, respectively, however the sensitivity is lower when BMI
(body mass index) is over 35 Kg/m2. Although this acceptable level of sensitivity it does not pro‐
vide reproducible quantitative information. US scoring system for fatty liver is based on hyper‐
echogenic liver tissue, the increased discrepancy of echo amplitude between liver and kidney
and the loss of echoes from the walls of the portal system [44]. US cannot differentiate between
steatosis and fibrosis, but with advance degrees of fibrosis an increase in coarse echoes without
posterior beam attenuation can be seen.
Features NORMAL MILD MODERATE SEVERE
Liver echotexture Liver parenchyma is homogeneous and
no difference in contrast between liver
and kidney
Slight increase in echo
pattern
Intermediate Gross discrepancy of the
increased hepatic to renal cortical
echogenicity
Echo penetration an
visibility of
diaphragm
Liver structure is clearly defined from the
surface to diaphragm. The outline of the
diaphragm is clearly visualized.
Mild attenuation of
sound beam through
the liver
Intermediate Marked attenuation of sound
beam through the liver, the
diaphragm is not visualized.
Clarity of liver blood
vessel structure
Vessel wall and lumen of vessel can
clearly visualized
Slight decrease
definition of portal
venule walls
Intermediate Only the main portal walls can be
visualized with absence of all
smaller portal venule walls
Table 8. Ultrasonographic grading system for diagnosis of fatty liver, adapted from [41].
Computer Tomography provides an accurate and a reliable visualization of whole liver, so
that not only diffuse but also focal fatty infiltration of the liver parenchyma can be accurately
diagnosed. CT enables the evaluation of absolute measurement of attenuation values which
are given in Hounsfield units, the difference of attenuation between liver and spleen as well as
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the calculation of the liver-to-spleen attenuation ratio, those correlate with steatosis degree.
Liver density as measured by CT attenuation units has been shown to have an inverse correla‐
tion to the degree of fatty infiltration. Non-enhanced CT provides a high performance in quali‐
tative diagnosis of hepatic steatosis when fatty infiltration is over 30%, obtaining 82% of
sensitivity and 100% specificity using histologic analysis of biopsies of liver donors as the refer‐
ence standard [45], however is not sensitive in detecting mild-to-moderate amounts of steato‐
sis between 5% and 30% [43]. New CT scanning techniques are developing, such as dual-
source/dual energy scanners, but their evaluation needs further studies. A drawback of this
technique is the liver iron overload because it increases the attenuation. This method is associ‐
ated with radiation exposure which limits its use in children.
Magnetic Resonance can detect steatosis by exploiting the difference of resonance frequen‐
cies between water and fat proton signals. The sensitivity and specificity of MRI in detecting
as low as 5% of liver fat infiltration are 85% and 100%, respectively [46]. The detection of the
fatty liver can be seen in “white/bright” when applying in-phase T1 images and “black”
when applying out-of-phase images, compared to the signal intensity of the spleen and par‐
aespinal muscles. Another technic of MR imaging with fat saturation may quantify more ac‐
curately liver fat infiltration, especially in patients who have fibrosis.
MR spectroscopy can reliably quantify even minimal steatosis, as low as 0,5% [47]. In has
been based on the ubiquitous protons hydrogen and phosphorus [48], and more than 5% of
fat content on MR spectroscopy indicates presence of steatosis [49]. Its routine application is
limited by cost and lack of availability, and it remains a research tool.
Methods (S/s) Advantages Disadvantage
Ultrasonography.
(60-95% / 84-100%)
Noninvasive, widely aviable, low cost, repetition,
Useful for screening
Operator dependent.
Qualitative assessment of steatosis.
Only accurate when moderate-to-severe fat
infiltration.
Computer tomography,
Contrast images.
(50-86% / 75-87%)
Noninvasive, semiquantitative assessment of fat
content.
Detects focal or diffuse infiltration.
Radiation exposure.
Iron overload, copper and fibrous tissue could be
confounding factors.
Not sensitive for mild-to-moderate amounts of
steatosis.
Magnetic resonance imaging
(85% / 100%)
Noninvasive, semiquantitative, and no radiation
exposure.
Detects focal or diffuse infiltration.
Limitation in patients with iron overload.
Not suitable for patients with claustrophobia or
implantable devices.
MR spectroscopy Noninvasive, reproducible, accurate quantification. High cost not widely available. Long time taking
images.
Table 9. Pro’s and con’s of radiologic modalities for the study of NAFLD. S: sensitivity; s: specificity. Adapted from [41].
US, CT and MR are insensitive in differentiating hepatic steatosis from NASH, and they can‐
not be used to stage fibrosis [43, 48]. But in the near future, a novel method based on MRI
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imaging and a new software will be able to stage fibrosis and to distinguish NASH from no-
NASH. Professor Romero-Gomez conducts this study and it will be soon published.
Table 9 summarizes advantages and disadvantages of these radiologic methods.
9. Non-invasive assesment in NAFLD
Liver biopsy remains a useful tool to confirm the diagnosis and exclude other disease or
helps to discover concomitant chronic liver disease. It provides prognostic information by
staging and grading this disease. At present non-invasive diagnostic markers could provide
a new tool for differentiating fatty liver from NASH as well as for grading /staging NAFLD.
The investigation of these new diagnostic methods comes from the well known drawbacks
of liver biopsy. These include sampling error, inadequate biopsy size, variability in patholo‐
gist interpretation, cost and associated morbidity (complications 0,3%, mortality rate 0,01%).
An ideal non-invasive test should be simple, reproducible, readily available, less expensive
than liver biopsy, able to predict the full spectrum of liver fibrosis stages, and reflect
changes occurring with therapy [48].
Some reviews provide an overview of the role of non-invasive test in NAFLD [48, 50, 51].
We will try to present many of these scores through a table (number 10) to summarize their
characteristics. AUROC is a numerical data that assess the performance of a scoring system.
AUROC value greater than 0,8 indicate good diagnostic performance. The closer the value
to 1, the better performing the scoring system.
SCORE [Reference] Variables Cutoff AUROC Sens. (%) Spec. (%) PPV (%) NPV (%)
NONINVASIVE DIAGNOSIS OF STEATOSIS
SteatoTest [52] 6 components of FibroTest-
ActiTest, BMI, cholesterol,
triglycerides, glucose
0,3
0,7
0,79-0,86 85 88 46
63
93
79
Fatty liver Index (FLI)
[53]
BMI, waist circumference,
triglycerides, GGT
<30
>70
0,85 87 86
NONINVASIVE ASSESSMENT IN NASH
Palekar [54] HA >55 mcg/l, age >50 years,
female gender, AST >45 UI/ml,
AAR >80.
≥3 0,763 73,7 65,7 68,2 71,4
CK-18 [17] CK-18 plasma (apoptosis
marker)
250 U/l 0,83 75 81
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SCORE [Reference] Variables Cutoff AUROC Sens. (%) Spec. (%) PPV (%) NPV (%)
oxNASH [55] Detection of lipid peroxidation
products by chromatography-
mass spectrometric
0,74-0,83 63-81 84-97
SHIMADA [56] Serum adiponectin, type 4
collagen 7s level, HOMA-IR
94 74 94 74
NASH Diagnostics
[57]*
CK-18, cleaved CK-18,
adiponectin, resistin
0,3825 0,73 71,4 72,7 83,3 57,1
NashTest [58] Age, gender, BMI, triglycerides,
cholesterol,
alfa-2macroglobulin, GGT,
haptoglobin, apolipoprotein-
A1, total bilirubin
0,79 29 98 91 71
NONINVASIVE MANAGEMENT OF FIBROSIS IN NAFLD
NAFLD fibrosis score
[59]
Age, BMI, IFG/diabetes, AAR,
platelet, albumin
≤1,455
≥0,676
0,88 56
90
93
85
Pediatric NAFLD
fibrosis index [60]
Age, waist circumference and
triglycerides.
≥9: rule in liver
fibrosis.
0,85 98,5 44,5
<3:rule out
fibrosis
75,4** 75**
**Pre-test probability:
69%
BARD score [61] BMI ≥28 =1, AAR ≥0,8 =2,
diabetes=1,
≥2: advanced
fibrosis
0,81 96
FIB-4 [62] Age, AST, platelet, ALT <1,3
>2,67
0,80 43
80
90
83
APRI [63] AST, platelet 0,98 Advanced fibrosis:
0,85
75 86 54 93
ELF [64] HA, TIMP1, P3NP. 0,3576 For severe fibrosis
0,90.
80 90 71 94
-0,1068 For moderate
fibrosis 0,82
70 80 70 80
ELF: -0,2070. No fibrosis 0,76 61 80 81 79
BAAT [65] Age ≥50years, BMI ≥28kg/m2
=1, triglycerides ≥7mmol/L=1,
ALT ≥2N
0-1, for septal
fibrosis
0,84 100 47 100
Fibrotest [66] 0,30 F0-1 VS F2-4:
075-085.
70 90
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SCORE [Reference] Variables Cutoff AUROC Sens. (%) Spec. (%) PPV (%) NPV (%)
F0-2 VS F3-4:
0,81-0,92
0,70 98 73
Fibrometer [67] Glucose, AST, platelets, ferritin,
ALT, weight, age.
<0,611 F0-1 vs F2-4:
0,936-0,952
ULTRASOUND BASED TECHNIQUES IN FIBROSIS DETECTION IN NAFLD
Fibroscan [68] Transient elastography 9,9 kPa
16 kPa
F ≥3: 0,99
F4: 0,998
100
100
93
93
77
86
100
100
ARFI [69] 4,24 kPa F0-2 vsF3-4: 0,90 90 90
ARFI [68] 1,77 m/sec
1,90 m/sec
F ≥3: 0,973
F4: 0,976
100
100
91
96
71
75
100
100
MAGNETIC RESONANCE IMAGING BASED TECHNIQUES
MR elastography[70] Discriminating NASH from
simple steatosis (SS)
2,74 kPa SS vs NASH: 0,93 94 73 85 89
Means:
- 2,51kPa.
- 3,24kPa.
- 4,16kPa.
Simple steatosis.
NASH no fibrosis.
With fibrosis
Abbreviations: AUROC: area under receiver operator curve. Sens.: Sensitivity; Spec.: Specificity; PPV: positive predictive
value; NPV: negative predictive value; BMI: body mass index; GGT: Gamma-glutamyl-transpeptidase; HA: hyaluronic
acid; AST: aspartate transaminase; AAR: AST/alanine aminotransferase, TIMP-1: tissue inhibitor of matrix metallopro‐
teinase 1; P3NP: aminoterminal peptide of pro-collagen III; ARFI: acoustic radiation force impulse; * Sample: bariatric
surgery patients. COMMENTS: BARD score can reliably exclude advance fibrosis, particularly among non-diabetics.
FIB-4, as happened with BARD score, is useful in excluding advance fibrosis due its high NPV. Transient elastography
and ARFI are based on the variation of the speed wave through liver tissue (generated by vibrator/short-duration
acoustic pulses, respectively), this can be measured and converted to a numerical value (in kPa and m/sec, respectively,
but ARFI could also be expressed as kPa) which is the liver stiffness and it is proportional to liver fibrosis. An important
difference between both systems is that ARFI consists in a probe which can be plugged to a common US machine so
both techniques can be performed at the same time.
Table 10. Non-invasive assessment of NAFLD.
APRI and FIB-4 have been evaluated in obese children and they might be useful in this special
population [71]. Pediatric NAFLD scores is a noninvasive model evaluated in obese children,
and it may help clinicians to predict liver fibrosis but external validation is needed [60].
In the future, new serologic markers, such as CD36, will help to differentiate more accurate‐
ly between NAFLD stages, we would be able to distinguish simple steatosis from NASH.
Although clinical and laboratory models may be useful in identifying a group of patients at
a low risk of advance fibrosis and liver biopsy might be avoided, they are not enough for
staging and prognostic purposes if patients are at risk of advance fibrosis [48]. NAFLD Prac‐
tice Guideline of 2012 recommends NAFLD fibrosis score to identify patients with higher
likelihood of having bridging fibrosis and/or cirrhosis [1].
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10. New diagnostic platforms in nafld
NAFLD is a disease with wide spectrum: from steatosis through inflammation to fibrosis
and finally cirrhosis and hepatocellular carcinoma, even in absence of cirrhosis [72]. The
strongest predictor of fibrosis progression in NAFLD is steatohepatitis. The most important
features are hepatocellular degeneration (ballooning) and inflammatory cell infiltration.
These new techniquesinclude genomics, metabolomics and proteomics.
Genomics. Gene expression studies provide an insight into possible mechanism of patho‐
genesis as well as potential biomarkers of disease. One method for studying gene expression
is micro-arrays of DNA. A study using this test found 34 gens with different expression in
NASH vs controls, these genes where implicated in lipid metabolism and extracellular ma‐
trix remodelling [73]. Another study compared gene expression in NASH-related cirrhosis
with other causes of cirrhosis. In NASH cirrhosis group genes involved in anti-oxidant
stress were underexpressed, along with genes involved in fatty and glucose metabolism
[74]. In our centre we used micro-arrays to study gene expression in obese patients with
NAFLD [75]. Obese patients with NASH without fibrosis show an overexpression of proin‐
flammatory and proapoptotic genes; and those with fibrosis show an overexpression of fi‐
brogenic genes, including the leptin receptor Ob-Rb.
Most recent genomic tests, such GWAS (Genome-wide association studies) provide a method
for evaluating a large number of single nucleotide polymorphisms (SNP) with the same experi‐
ment. A study performed with a GWAS study found a SNP in farnesyldiphosfatasefarnesyl‐
transferase 1 (FDFT1) which was associated with different histological parameters (a SNP with
portal inflammation and another different SNP with fibrosis stage) and the total NAFLD activ‐
ity score [76]. In an earlier GWAS study [77], an SNP in PNPA3 (adiponutrin/patatin-like phos‐
pholipase-3) was strongly associated with both hepatic fat content and hepatic inflammation.
The prevalence of this mutation may explain the difference in susceptibility to NAFLD seen in
different ethnicities [77]. A subsequent study [78], confirmed the relationship between this
SNP and histological score, the no association with metabolic syndrome.
These studies are incredibly interesting and they could help the development of new nonin‐
vasive markers, nevertheless all of them share limitations, mainly concerning to sample size.
It is easily understandable given the fact that they use expensive and complex tools [51].
Proteomics. Proteomic tools look specifically at protein expression patterns and profiles.
There are several approaches to proteomic studies depending on the used tool. These tools
are complex; they are based on diverse types of mass-spectrometry. For more detailed infor‐
mation refer to [79, 80]. The different proteomic platforms support the use of either liver tis‐
sue or blood. This platform allows identifying, quantifying and comparing proteins in the
study groups of interest. That novel approach has been applied for the study of NAFLD
[81-84]. These studies have found several proteins related to disease progression: alfa and
beta-hemoglobin [84], lumican and FABP1 (fatty acid binding protein-1) [82]; and finally fi‐
brinogen beta-chain, retinol binding protein-4, serum amiloyd p-component, lumican, trans‐
grelin-2 and CD5-like antigen, in 6-panel model and complement component 7, transgrelin-2
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and insulin grow factor acid labile subunit, in a 3-panel model. These panels performed in
the diagnosis of the diverse NAFLD stages get an area under the receiver operator curve
(AUROC) ranging from 0,83 to 0,91 [83].
Metabolomics. In the natural history of NAFLD the progression to hepatic fibrosis occurs
only in 10 to 25% of cases, leading to cirrhosis, end-stage liver disease or hepatocellular car‐
cinoma. The strongest predictor of fibrotic progression, apart from pre-existing fibrosis, is
steatohepatisis. A two-hit model has been proposed as an explanation for why some pa‐
tients progress to NASH. In a first step, because of insulin resistance, adipose tissue has en‐
hanced triglyceride lipolysis, which leads to increased serum free fatty acids, and impaired
hepatic triglyceride export. In this model, hepaticsteatosis (hit 1) exposes the liver parenchy‐
ma to environmental and extracellular hepatic insults (hit 2), leading to inflammation, stea‐
tonecrosis and fibrosis. Impaired mitochondrial oxidation and lipid export may also
contribute to hepatic fat deposition.
Leptin system is also implicated, and its receptor expression is related to fibrosis degree [85].
As it was explained in the introduction, irisin is a newly identified hormone. Irisin is pro‐
duced in muscle cells induced in exercise [86-88]. Irisin activates changes in adipose tissue,
and make its change from white adipose tissue to brown adipose tissue, and this causes a
significant increase in total body energy expenditure and resistance to obesity-linked insulin
resistance. So this advance opens new pathogenic pathways in NAFLD.
Inflammation is considered to be the central clue for the progression of NAFLD, the origins
and components are considered in this review [89]. Hepatocytes injured by toxic lipid mole‐
cules play a central role in the recruitment of innate immunity involving Toll-like receptors
(TLR), Kuppfer cells, lymphocytes and neutrophils and possibly inflammasome. On this
way, a study was carried to determine the lipidomic signature in NAFLD [90]. Using proteo‐
mic tools (mass spectrometry) the investigators found metabolites from nonenzymatic oxi‐
dation product of arachidonic acid and from impaired peroxisomal polyunsaturated fatty
acid (PUFA). This study links to another, where investigators characterize metabolic profile
to distinguish steatosis and NASH [91], they also found arachidonic acid, among other sub‐
stances, relation to NASH and fibrosis. Metabolomics analysis was performed to NAFLD
patients showing a lower concentrations of glutathione, an antioxidant substance, in this
group [92].
The key pro-inflammatory signalling pathways in NASH are nuclear factor-kappa B (NF-
kB) and c-Jun N-terminal kinase (JNK). It could be possible that inflammation in NASH
could originate outside the liver. Gut microbiota, the related Kupffer/TLR response, in‐
flamed adipose tissue and circulating inflammatory cell can contribute or act as co-factors
that triggers or maintain hepatic injury. In a study conducted in our centre to study the rela‐
tionship between endotoxemia and NAFLD, we found higher levels of LBP (Lipopolysac‐
charide-binding protein) in patients with NASH when compared to patients with simple
steatosis [93]. The LBP increase correlates with the level of tumor necrosis factor alfa (TNF-
alfa) which is overexpressed in patient with NASH and significant fibrosis. [94] Detailed in‐
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formation in pathophysiology of NAFLD and NASH is not the aim of this paper, if you are
interested refer to this review [89].
11. Conclusion
NAFLD is an emerging problem. The study of pathology is ever evolving which is allowing
the development of new therapeutic targets, and the emergence of new diagnostic techni‐
ques allow better identification of patients who will benefit from new treatments.
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